Form 4: RAPT Therapeutics CMO Granted Significant Stock Options

RAPT Therapeutics, Inc. Chief Medical Officer William Ho was granted 75,000 employee stock options with a vesting schedule commencing June 20, 2025.

Summary

• William Ho, the Chief Medical Officer of RAPT Therapeutics, Inc. (RAPT), was granted 75,000 employee stock options.
• The options have an exercise price of $7.43 per share.
• Vesting for these options is scheduled to begin on June 20, 2025, with 1/48th of the shares vesting on each monthly anniversary of this date.
• The options are set to expire on June 19, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns the executive's financial interests with the long-term performance of the company and shareholder value. It is a routine compensation event and does not indicate any immediate operational or financial issues.

Positives

• The grant of stock options to the Chief Medical Officer aligns executive incentives with the long-term performance and shareholder value creation of RAPT Therapeutics.

Future Outlook

The document details a standard executive compensation grant with a defined vesting schedule extending over 48 months, indicating a long-term incentive structure for the Chief Medical Officer.

Industry Context

The grant of stock options is a common and standard practice in the biotechnology and pharmaceutical industries for executive compensation. It is widely used to attract, retain, and incentivize key personnel by linking their financial interests directly to the company's stock performance and long-term success.

Comparison to Industry Standards

• The use of employee stock options as a compensation tool for a Chief Medical Officer is a standard practice across the biotech and pharmaceutical sectors, comparable to compensation structures at companies like Moderna, BioNTech, or Gilead Sciences, which frequently utilize equity-based incentives.
• The vesting schedule of 1/48th monthly over four years is a typical industry standard for executive equity grants, designed to encourage long-term commitment and performance.

Related Party Transactions

• The transaction represents an equity compensation grant to a key executive (Chief Medical Officer), which is a common form of related-party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grant of options creates potential future dilution if exercised, but also serves to align the Chief Medical Officer's incentives with shareholder value creation.
• Employees: This transaction reflects standard executive compensation practices within the company.

Next Steps

• Continued monthly vesting of the 75,000 stock options for William Ho, commencing June 20, 2025.

Key Dates

Keywords

RAPT Therapeutics, RAPT, stock options, employee stock option, William Ho, Chief Medical Officer, CMO, executive compensation, SEC Form 4, insider transaction